Status:

COMPLETED

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma

Lead Sponsor:

GlaxoSmithKline

Conditions:

Asthma

Eligibility:

All Genders

12+ years

Phase:

PHASE3

Brief Summary

A randomised, double-blind, placebo-controlled (with rescue medication), multi-centre study to evaluate the efficacy and safety of inhaled fluticasone furoate in the treatment of persistent asthma in ...

Detailed Description

This will be a multi-centre, randomised, placebo controlled (with rescue medication), double-blind, parallel group study. Subjects meeting all the inclusion criteria and none of the exclusion criteria...

Eligibility Criteria

Inclusion

  • Signed informed consent
  • Outpatient at least 12 years of age with diagnosis of asthma at least 12 weeks before first visit
  • Both genders; females of child bearing potential must be willing to use appropriate contraception during the study
  • Pre-bronchodilator FEV1 of at least 60% predicted
  • FEV1 reversibility of at least 12% and 200mls
  • Current asthma therapy that includes a non-corticosteroid controller and/or short-acting beta agonist

Exclusion

  • History of life-threatening asthma exacerbation within the past 10 years
  • Asthma exacerbation requiring treatment with oral corticosteroids within the last 3 months or that required overnight hospital stay within 6 months
  • Current or recent respiratory infection or current oral candida infection
  • Presence of another significant respiratory disease or medical condition that is not controlled or that could affect subject safety or study outcome
  • Known or suspected allergy to study drug or materials
  • Taking another investigational medication or prohibited medication during the study
  • Previous treatment with inhaled fluticasone furoate in a phase II or III study
  • Current smokers or former smokers with significant tobacco exposure
  • Children in Care

Key Trial Info

Start Date :

September 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2012

Estimated Enrollment :

248 Patients enrolled

Trial Details

Trial ID

NCT01436071

Start Date

September 1 2011

End Date

August 1 2012

Last Update

January 11 2017

Active Locations (24)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (24 locations)

1

GSK Investigational Site

Long Beach, California, United States, 90808

2

GSK Investigational Site

Los Angeles, California, United States, 90025

3

GSK Investigational Site

Newport Beach, California, United States, 92663

4

GSK Investigational Site

Albany, Georgia, United States, 31707